London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.

Based at Myricx’s London, UK facilities, Jonathon joins the company at a time when its multiple N-myristoyltransferase inhibitor (NMTi)-ADC programs are advancing towards clinical development and where partnership options are being explored. Having nominated its lead development candidate, Myricx expects to enter human clinical trials in 2026.

Jonathon joins Myricx from Alchemab Therapeutics, where he most recently held the role of Senior Director of Business Development and New Product Planning. Previously, he was Director, Business Development and Portfolio Strategy at Orchard Therapeutics. Earlier in his career Jonathon was a Manager and Consultant at IQVIA.

Jonathon has a Ph.D. in Medical Research, a B.Sc. in Molecular Biology and a B.Com in Business Economics all from the University of New South Wales, Australia.

Robin Carr, Ph.D., CEO at Myricx Bio said, “We are delighted to welcome Jonathon to Myricx as we continue our company growth and make exciting progress with our NMT inhibitor platform and pipeline. With a successful track record in business development, he adds further to the strength of our team as we continue to advance toward clinical development.”

Jonathon Marks-Bluth, Ph.D., VP, Business Development at Myricx Bio said, “I’m impressed with Myricx’s NMT inhibitor chemistry platform and its potential to bring much needed novel payloads to antibody-drug conjugate (ADC) therapies. The company also has an exciting pipeline of ADCs that address significant unmet needs in oncology. I’m excited to join the Myricx team and be given the opportunity to help guide and execute on its global partnering strategy at this important time.”

Over the past 12 months since securing its £90 million ($114 million) Series A financing, Myricx has moved to dedicated facilities in London, expanded its leadership and R&D teams including adding its first US-based team member, and plans further appointments in the future.

-Ends-

Notes to Editors:

About Myricx Bio - www.myricxbio.com

Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio, [email protected]

Media enquiries
Sue Charles, Charles Consultants, [email protected], +44 (0)7986 72658